QR01019 potassium salt

QR01019 potassium salt is a small molecule neprilysin (neutral endopeptidase, NEP) inhibitor developed by Wuhan Createrna Science and Technology for the treatment of cardiovascular diseases, specifically essential hypertension. It is designed to inhibit the breakdown of natriuretic peptides, thereby promoting vasodilation, natriuresis, and diuresis. In clinical development, QR01019 is being evaluated both as a monotherapy and as a primary component of **QR12000**, a compound tablet that combines QR01019 with the angiotensin II receptor blocker (ARB) valsartan. This combination strategy aims to provide a dual-acting angiotensin receptor-neprilysin inhibitor (ARNI) effect, similar to the mechanism of sacubitril/valsartan, to manage moderate to severe hypertension more effectively than traditional ARB monotherapy.